A Comparative Study of Six Methods to Measure Human Contrast Vision

Uppsala University

Status: Unknown

Conditions: Methods to Measure Contrast Vision

Treatments: Device: Pelli-Robson; Device: UCST-V2; Device: UCST-V1; Device: UCST-V3; Device: Quick-CSF (QCSF); Device: Optec 6500

Study type: Interventional

Funder types: Other

Identifiers

NCT02767284

UCST-01.2014

Details and patient eligibility

About

This study evaluates the relative performance of different methods to measure the human spectral contrast sensitivity function (CSF).

Full description

The human spectral contrast sensitivity function (CSF) is a better way to estimate human vision than letter charts commonly used by ophthalmologists, optometrists and opticians.

The current methods used to measure the CSF are often unreliable, due to high variability between measurements. This study will compare four (4) new tests with two (2) currently used standard tests. The contrast sensitivity function will be measured using all of the six (6) methods three times (3) in each of the two (2) eyes at two (2) occasions. Each subjects CSF will be measured 6x3x2x2 = 72 times.

In addition, for each of the CSF measurements, the time used to measure the CSF and number of background variables for the subjects will be recorded.

After informed consent is obtained, the subjects will undergo a visual examination. If they match the inclusion criteria they will be included. At that time or at their earliest possible convenience, their CSF will be measured using the six methods and some background information will be recorded.

The follow-up measurement occasion will occur between 4 to 6 weeks (28 to 42 days) after the first.

To facilitate comparison with previous studies, the CSF-measurements (in rel. contrast/cycles/degree) will be converted to a log (Base 10 logarithm) scale. The unit will thus be log CSF (LCSF) [log[relative contrast]/log[cycles/per degree]].

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Normal best corrected visual acuity: LogMAR = 0
• No current or previous eye disease in either eye.
• Student at Uppsala University

Exclusion criteria

• Previous surgery in any eye
• Inability to follow the test procedure.

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

40 participants in 6 patient groups

UCST-V1

Experimental group

Description:

The UCST-V1 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)

Treatment:

Device: UCST-V1

UCST-V2

Experimental group

Description:

The UCST-V2 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)

Treatment:

Device: UCST-V2

UCST-V3

Experimental group

Description:

The UCST-V3 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)

Treatment:

Device: UCST-V3

Quick-CSF

Experimental group

Description:

The Quick-CSF test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)

Treatment:

Device: Quick-CSF (QCSF)

Pelli-Robson

Active Comparator group

Description:

The Pelli-Robson contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)

Treatment:

Device: Pelli-Robson

Optec 6500

Active Comparator group

Description:

The Optec 6500 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)

Treatment:

Device: Optec 6500